DOI:
10.1055/s-00000054
Pharmacopsychiatry
LinksClose Window
References
Baird-Bellaire S, Behrle JA, Parker VD. et al.
An open-label, single-dose, parallel-group study of the effects of chronic hepatic impairment on the safety and pharmacokinetics of desvenlafaxine.
Clin Ther 2013;
35: 782-794
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.